# KEYNOTE-F21 (NCT04225117)

> A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04225117
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Astellas Pharma Global Development, Inc.
- Conditions: Locally Advanced or Metastatic Malignant Solid Tumors
- Interventions: enfortumab vedotin; pembrolizumab
- Enrollment: 329
- Primary outcome: Cohorts 1-8: Confirmed Overall Response Rate (ORR) (Complete Response [CR] and Partial Response [PR]) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (V)1.1 Per Investigator Assessment
- Primary outcome: Cohort 9: Confirmed ORR (CR and PR) Per RECIST V1.1 Per Investigator Assessment

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 9
- YouTube: 4
- Podcasts: 4

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=keynote-f21-nct04225117

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04225117", "email": "<work email>"}; the inbox owner confirms by the emailed link.